Description
Meningitis - Pipeline Analysis and Market Forecasts to 2016
Summary
“Meningitis – Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global meningitis market. The report identifies the key trends shaping and driving the global meningitis market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to bring significant shifts in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global meningitis sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
The of the report includes:
- Annualized global meningitis disease market revenues data from 2006 to 2009, forecast forward for seven years to 2016.
- Geographic markets covered in this report include the US, Europe and Rest of the World.
- Pipeline analysis data providing a split across vaccines and drugs. Key vaccine classes include conjugated and recombinant vaccines.
- Analysis of the current and future market competition in the global meningitis market. Key market players covered are Novartis, GlaxoSmithKline, Sanofi-aventis (Sanofi Pasteur), InterMune and Merck.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessments, market characterization, unmet needs and the implications for the future market associated with meningitis.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global meningitis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global meningitis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain the competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global meningitis market landscape? Identify, understand and capitalize.
Companies Mentioned
Novartis
GlaxoSmithKline
Sanofi-aventis
InterMune Inc
Merck & Co., Inc
Global Healthcare Industry
Table of Contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Meningitis: Market Characterization 5
2.1 Overview 5
2.2 Meningitis Market Size 5
2.3 Meningitis Market Forecast and CAGR 6
2.4 Drivers and Barriers for Meningitis Market 7
2.4.1 Drivers for Meningitis Market 7
2.4.2 Barriers for Meningitis Market 7
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 9
3 Meningitis Market: Competitive Assessment 10
3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.3 Product Profile for the Major Marketed Products in Meningitis Market 11
3.3.1 Menactra 11
3.3.2 ActHIB 12
3.3.3 Merrem 12
3.3.4 AmBisome 13
3.4 Major Marketed Products Comparison in Meningitis Market 15
3.5 Key Takeaway 15
4 Meningitis Market: Pipeline Assessment 16
4.1 Overview 16
4.2 Strategic Pipeline Assessment 16
4.2.1 Technology Trends Analytical Framework 16
4.3 Meningitis – Promising Vaccines/Drugs under Clinical Development 17
4.4 Molecule Profile for Promising Vaccines/Drugs under Clinical Development 18
4.4.1 MenACWY 18
4.4.2 Meningitis B vaccine (MenB vaccine) 18
4.5 Meningitis Market – Clinical Pipeline by Vaccine Class 19
4.6 Meningitis Pipeline – Pipeline by Clinical Phases of Development 19
4.6.1 Meningitis – Phase III Clinical Pipeline 20
4.6.2 Meningitis – Phase II Clinical Pipeline 20
4.6.3 Meningitis – Phase I Clinical Pipeline 21
4.6.4 Meningitis – Discovery and Preclinical Pipeline 21
4.7 Discontinued / Suspended Products for Meningitis 22
4.8 Key Takeaway 22
5 Global Meningitis Market: Implications for Future Market Competition 23
6 Global Meningitis Market: Future Players in Meningitis Market 24
6.1 Introduction 24
6.2 Novartis 24
6.2.1 Company Overview 24
6.2.2 Business Description 25
6.2.3 Novartis - Infectious Diseases Pipeline 25
6.2.4 Novartis - Meningitis Vaccines Pipeline 26
6.3 GlaxoSmithKline 26
6.3.1 Company Overview 26
6.3.2 Business Description 26
6.3.3 GlaxoSmithKline - Infectious Diseases Pipeline 27
6.3.4 GlaxoSmithKline - Meningitis Pipeline 27
6.4 Sanofi-aventis 28
6.4.1 Company Overview 28
6.4.2 Business Description 28
6.4.3 Sanofi-aventis Infectious Diseases Pipeline 29
6.4.4 Sanofi-aventis - Meningitis Pipeline 29
6.5 InterMune Inc. 29
6.5.1 Company Overview 29
6.5.2 Business Description 29
6.5.3 InterMune - Infectious Diseases Pipeline 30
6.5.4 InterMune - Meningitis Pipeline 30
6.6 Merck & Co., Inc. 31
6.6.1 Company Overview 31
6.6.2 Business Description 31
6.6.3 Merck - Infectious Diseases Pipeline 32
6.6.4 Merck - Meningitis Pipeline 32
7 Global Meningitis Market: Appendix 33
7.1 Market Definitions 33
7.2 Abbreviations 33
7.3 Research Methodology 33
7.3.1 Coverage 34
7.3.2 Secondary Research 34
7.3.3 Forecasting 35
7.3.4 Primary Research 38
7.3.5 Expert Panel Validation 38
7.4 Contact Us 38
7.5 Disclaimer 38
7.6 Sources 39
List of Tables
1.1 List of Tables
Table 1: Global Meningitis Market, Revenues ($m), 2006-2016 6
Table 2: Major Marketed Products Comparison in Meningitis Market, 2010 15
Table 3: Meningitis – Most Promising Vaccines/Drugs Under Clinical Development, 2010 17
Table 4: Meningitis – Phase III Clinical Pipeline, 2010 20
Table 5: Meningitis – Phase II Clinical Pipeline, 2010 20
Table 6: Meningitis – Phase I Clinical Pipeline, 2010 21
Table 7: Meningitis – Discovery and Preclinical Pipeline, 2010 21
Table 8: List of Discontinued Products for Meningitis, 2010 22
Table 9: Novartis - Infectious Diseases Pipeline, 2010 25
Table 10: Novartis - Meningitis Pipeline, 2010 26
Table 11: GlaxoSmithKline - Infectious Diseases Pipeline, 2010 27
Table 12: GlaxoSmithKline - Meningitis Pipeline, 2010 27
Table 13: Sanofi-aventis - Infectious Diseases Pipeline, 2010 29
Table 14: Sanofi-aventis - Meningitis Pipeline, 2010 29
Table 15: InterMune - Infectious Diseases Pipeline, 2010 30
Table 16: InterMune - Meningitis Pipeline, 2010 30
Table 17: Merck - Infectious Diseases Pipeline, 2010 32
Table 18: Merck - Meningitis Pipeline, 2010 32
List of Figures
1.2 List of Figures
Figure 1: Global Meningitis Market Forecast, Revenues ($m), 2006-2016 6
Figure 2: Opportunity and Unmet Need in the Meningitis Market, 2010 9
Figure 3: Strategic Competitor Assessment of the Meningitis Market, 2010 10
Figure 4: Technology Trends Analytic Framework-Meningitis Market, 2010 16
Figure 5: Technology Trends Analytic Framework – Description- Meningitis Market, 2010 17
Figure 6: Meningitis Market – Clinical Pipeline by Class of Vaccine, 2010 19
Figure 7: Meningitis Pipeline by Phase of Clinical Development, 2010 19
Figure 8: Implications For Future Market Competition in the Meningitis Market, 2010 23
Figure 9: Meningitis Market – Clinical Pipeline by Company, 2010 24
Figure 10: GlobalData Methodology 34
Figure 11: GlobalData Market Forecasting Model 37
